| PLCgamma1 in dopamine neurons critically regulates striatal dopamine release via VMAT2 and synapsin III. | PLCγ1 in dopamine neurons critically regulates striatal dopamine release via VMAT2 and synapsin III.
Kim HY, Lee J, Kim HJ, Lee BE, Jeong J, Cho EJ, Jang HJ, Shin KJ, Kim MJ, Chae YC, Lee SE, Myung K, Baik JH, Suh PG, Kim JI., Free PMC Article | 12/5/2023 |
| Targeting barrel field spiny stellate cells using a vesicular monoaminergic transporter 2-Cre mouse line. | Targeting barrel field spiny stellate cells using a vesicular monoaminergic transporter 2-Cre mouse line.
Freitag FB, Ahemaiti A, Weman HM, Ambroz K, Lagerström MC., Free PMC Article | 11/13/2021 |
| Vesicular monoamine transporter 2 mediates fear behavior in mice. | Vesicular monoamine transporter 2 mediates fear behavior in mice.
Branco RC, Burkett JP, Black CA, Winokur E, Ellsworth W, Dhamsania RK, Lohr KM, Schroeder JP, Weinshenker D, Jovanovic T, Miller GW., Free PMC Article | 07/17/2021 |
| VMAT2 Safeguards beta-Cells Against Dopamine Cytotoxicity Under High-Fat Diet-Induced Stress. | VMAT2 Safeguards β-Cells Against Dopamine Cytotoxicity Under High-Fat Diet-Induced Stress.
Sakano D, Uefune F, Tokuma H, Sonoda Y, Matsuura K, Takeda N, Nakagata N, Kume K, Shiraki N, Kume S., Free PMC Article | 02/2/2021 |
| Reduced VMAT2 expression impairs the neurogenesis in the subventricular zone and olfactory bulb. | Reduced VMAT2 expression exacerbates the hyposmia in the MPTP model of Parkinson's disease.
Ma K, Han C, Zhang G, Guo X, Xia Y, Wan F, Yin S, Kou L, Liu L, Huang J, Xiong N, Wang T. | 05/2/2020 |
| This study highlights a non-cytotoxic role of dopamine in a genetic model of VMAT2 deletion exclusively in nigrostriatal neurons. | Genetic elimination of dopamine vesicular stocks in the nigrostriatal pathway replicates Parkinson's disease motor symptoms without neuronal degeneration in adult mice.
Isingrini E, Guinaudie C, C Perret L, Rainer Q, Moquin L, Gratton A, Giros B., Free PMC Article | 06/29/2019 |
| results confirm the role of VMAT2 in the protection of vulnerable nigrostriatal dopamine neurons and may also provide new insight into the side effects of L-DOPA treatments in Parkinson's disease | Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals.
Lohr KM, Chen M, Hoffman CA, McDaniel MJ, Stout KA, Dunn AR, Wang M, Bernstein AI, Miller GW., Free PMC Article | 04/7/2018 |
| Study identified an importance for VMAT2-mediated neurotransmission in mediating hedonic feeding and binge-like eating behavior, providing novel insight on the interactive roles of leptin and dopamine, two of the most extensively studied brain systems, in obesity development. | VMAT2-Mediated Neurotransmission from Midbrain Leptin Receptor Neurons in Feeding Regulation.
Xu Y, Lu Y, Xu P, Mangieri LR, Isingrini E, Xu Y, Giros B, Tong Q., Free PMC Article | 03/24/2018 |
| In vivo imaging of the striatal vesicular monoamine transporter type 2 (VMAT2) distribution using 18F-FP-(+)-DTBZ animal PET is a useful method to evaluate the efficacy of therapeutic drugs i.e., magnolol, for the management of Parkinson's disease . | Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging.
Weng CC, Chen ZA, Chao KT, Ee TW, Lin KJ, Chan MH, Hsiao IT, Yen TC, Kung MP, Hsu CH, Wey SP., Free PMC Article | 09/2/2017 |
| Intravenous use of a psychostimulant drug containing methcathinone (ephedrone) and manganese causes an irreversible extrapyramidal syndrome; study reproduced the syndrome in mice to evaluate dopaminergic damage. Increased [(11)C]dihydrotetrabenazine binding may indicate vesicular monoamine transporter type 2 (VMAT2) function is altered. | Increased striatal VMAT2 binding in mice after chronic administration of methcathinone and manganese.
Asser A, Kõks S, Snellman A, Haaparanta-Solin M, Arponen E, Grönroos T, Nairismägi J, Bergquist J, Soomets U, Piip P, Eltermaa M, Sauk M, Lindmäe H, Rinne JO, Taba P. | 07/29/2017 |
| In contrast to their loss of catecholamine neurons of the substantia nigra and locus ceruleus, aged VMAT2 LO mice do not exhibit a change in the number of serotonergic (TPH2+) neurons within the dorsal raphe | Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration.
Alter SP, Stout KA, Lohr KM, Taylor TN, Shepherd KR, Wang M, Guillot TS, Miller GW., Free PMC Article | 04/30/2016 |
| Rotenone induces dopamine neuron death through a series of sequential events including microtubule destabilization, JNK3 activation, VMAT2 inhibition, accumulation of cytosolic dopamine, and generation of ROS. | JNK inhibition of VMAT2 contributes to rotenone-induced oxidative stress and dopamine neuron death.
Choi WS, Kim HW, Xia Z., Free PMC Article | 03/28/2015 |
| increased release of dopamine and neuroprotection from MPTP toxicity in the VMAT2-overexpressing mice suggest that interventions aimed at enhancing vesicular capacity may be of therapeutic benefit in Parkinson disease | Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo.
Lohr KM, Bernstein AI, Stout KA, Dunn AR, Lazo CR, Alter SP, Wang M, Li Y, Fan X, Hess EJ, Yi H, Vecchio LM, Goldstein DS, Guillot TS, Salahpour A, Miller GW., Free PMC Article | 09/20/2014 |
| The coordinate loss of dopamine and norepinephrine neurons in VMAT2 LO mice parallels the pattern of neurodegeneration that occurs in human PD. | Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.
Taylor TN, Alter SP, Wang M, Goldstein DS, Miller GW., Free PMC Article | 06/7/2014 |
| findings support the idea that altered DAT and VMAT2 expression affect age-related changes in dopaminergic function. | Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems.
Hall FS, Itokawa K, Schmitt A, Moessner R, Sora I, Lesch KP, Uhl GR., Free PMC Article | 06/7/2014 |
| Data suggest that pancreatic islets of mice and rats do not contain VMAT2, except in mast cells and sympathetic nerve terminals that innervate the islets. | Species-specific vesicular monoamine transporter 2 (VMAT2) expression in mammalian pancreatic beta cells: implications for optimising radioligand-based human beta cell mass (BCM) imaging in animal models.
Schäfer MK, Hartwig NR, Kalmbach N, Klietz M, Anlauf M, Eiden LE, Weihe E., Free PMC Article | 11/2/2013 |
| VMAT2 expression was increased by Nurr1 gene activation in lactacystin-lesioned mice. | Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease.
Zhang Z, Li X, Xie WJ, Tuo H, Hintermann S, Jankovic J, Le W. | 06/8/2013 |
| Data show that alpha-synuclein transcription is inversely correlated with neurite growth and VMAT2 expression, and inhibition of RhoA leads to a decrease in alpha-synuclein. | Rho GTPase regulation of α-synuclein and VMAT2: implications for pathogenesis of Parkinson's disease.
Zhou Z, Kim J, Insolera R, Peng X, Fink DJ, Mata M., Free PMC Article | 02/18/2012 |
| The expression of VMAT2 is increased significantly in hippocampal formation of 14-3-3 epsilon knockout mouse model compared to that of wild-type littermates. | Immunohistochemical study of vesicle monoamine transporter 2 in the hippocampal region of genetic animal model of schizophrenia.
Iritani S, Sekiguchi H, Habuchi C, Hikita T, Taya S, Kaibuchi K, Ozaki N. | 08/20/2011 |
| VMAT2 up-regulation might be a compensatory mechanism to restore and maintain synaptic transmission in dopaminergic midbrain neurons during nicotine withdrawal. | Increased expression of VMAT2 in dopaminergic neurons during nicotine withdrawal.
Duchemin AM, Zhang H, Neff NH, Hadjiconstantinou M. | 02/8/2010 |
| interaction between DAT and VMAT-2 function is more prevalent in female mice; and the +/- DAT mutation affects VMAT-2 function through an indirect mechanism, that does not involve an alteration in VMAT-2 protein or mRNA. | Genetic alteration in the dopamine transporter differentially affects male and female nigrostriatal transporter systems.
Ji J, Bourque M, Di Paolo T, Dluzen DE. | 01/21/2010 |
| female mice may have a greater amount/activity of VMAT2 function | Differences in reserpine-induced striatal dopamine output and content between female and male mice: implications for sex differences in vesicular monoamine transporter 2 function.
Dluzen DE, Bhatt S, McDermott JL. | 01/21/2010 |
| The ability of PACAP38 to increase VMAT2 expression suggests that PACAP38 signaling pathways may constitute a novel therapeutic approach to treat and prevent disorders of dopamine storage. | PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity.
Guillot TS, Richardson JR, Wang MZ, Li YJ, Taylor TN, Ciliax BJ, Zachrisson O, Mercer A, Miller GW., Free PMC Article | 01/21/2010 |
| Elevated markers of neurotoxicity in VMAT2 LO mice and cultures suggest that the capacity to store DA determines the amount of oxidative stress and neurodegeneration after METH administration. | Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis.
Guillot TS, Shepherd KR, Richardson JR, Wang MZ, Li Y, Emson PC, Miller GW., Free PMC Article | 01/21/2010 |
| demonstrates the efficacy of metabolomics as a functional genomics phenotyping tool for mouse models of neurological disorders, and indicates that mild reductions in the expression of VMAT2 affect normal brain metabolism | A metabolomic study of brain tissues from aged mice with low expression of the vesicular monoamine transporter 2 (VMAT2) gene.
Salek RM, Colebrooke RE, Macintosh R, Lynch PJ, Sweatman BC, Emson PC, Griffin JL. | 01/21/2010 |